Table 1.
Baseline characteristics of chronically supported clinically stable LVAD patients.
| Characteristic | N=18 |
|---|---|
| Age, years | 61 (56,65) |
| Duration of HF, years | 4.6 (2.4,8.5) |
| Duration of LVAD, months | 6.9 (4.8,9.7) |
| Sex, male | 15 (83) |
| Coronary Artery Disease | 10 (56) |
| Prior Myocardial Infarction | 9 (50) |
| Prior PCI | 10 (56) |
| Prior CABG | 4 (22) |
| Sarcoidosis | 2 (11) |
| Hx/o Hypertension | 7 (39) |
| Diabetes mellitus | 7 (39) |
| Chronic kidney disease, eGFR < 60ml/min/ 1.73m2 | 2 (11) |
| Body mass index, kg/m2 | 27 (24,31) |
| Current smoker | 2 (11) |
| ACEI or ARB | 15 (83) |
| Beta blocker | 18 (100) |
| Aldosterone antagonist | 8 (44) |
| Hydralazine | 1 (6) |
| Nitrates | 1 (6) |
| Diuretics | 11 (61) |
| Digoxin | 1 (6) |
| Statin | 13 (72) |
| Aspirin | 18 (100) |
| Warfarin | 18 (100) |
| Cardiac resynchronization therapy | 8 (44) |
| Implantable cardioverter defibrillator | 17 (94) |
Data presented as median (IQR) or counts (%). HF = heart failure; LVAD = left ventricular assist device; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; eGFR = estimated glomerular filtration rate. ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker.